Connor, Clark & Lunn Investment Management Ltd. Vaxcyte, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$20 Billion
Q4 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$70.52 - $117.12 $1.84 Million - $3.06 Million	26,096 Added 59.39%	70,037 $8 Million
Q2 2024 Aug 09, 2024	SELL	$60.06 - $78.77 $109,609 - $143,755	-1,825 Reduced 3.99%	43,941 $3.32 Million
Q1 2024 May 09, 2024	BUY	$59.79 - $81.05 $2.74 Million - $3.71 Million	45,766 New	45,766 $3.13 Million

Others Institutions Holding PCVX

# of Institutions

350

Shares Held

130M

Call Options Held

539K

Put Options Held

253K

Vanguard Group Inc Valley Forge, PA

12M
Shares

$883 Million
0.02% of portfolio
Janus Henderson Group PLC London, X0

10.6M
Shares

$781 Million
0.46% of portfolio
Black Rock Inc. New York, NY

9.94M
Shares

$734 Million
0.02% of portfolio
Ra Capital Management, L.P. Boston, MA

8.69M
Shares

$641 Million
11.52% of portfolio
Capital Research Global Investors Los Angeles, CA

6.21M
Shares

$458 Million
0.11% of portfolio

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $4.38B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account